Swiss National Bank Purchases 4,000 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Swiss National Bank increased its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 274,000 shares of the company’s stock after purchasing an additional 4,000 shares during the quarter. Swiss National Bank’s holdings in ImmunityBio were worth $701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. State Street Corp increased its position in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after purchasing an additional 790,408 shares during the period. Barclays PLC boosted its stake in shares of ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after purchasing an additional 202,248 shares in the last quarter. XTX Topco Ltd increased its position in shares of ImmunityBio by 309.4% during the third quarter. XTX Topco Ltd now owns 92,910 shares of the company’s stock valued at $346,000 after buying an additional 70,215 shares during the period. Intech Investment Management LLC purchased a new position in shares of ImmunityBio during the third quarter valued at about $253,000. Finally, Raymond James Financial Inc. bought a new position in ImmunityBio in the fourth quarter worth about $172,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Analyst Ratings Changes

IBRX has been the topic of several research reports. BTIG Research began coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective on the stock. D. Boral Capital restated a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of ImmunityBio in a report on Thursday, March 13th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ImmunityBio currently has a consensus rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Stock Performance

Shares of IBRX opened at $3.14 on Friday. The firm’s 50-day simple moving average is $3.13 and its two-hundred day simple moving average is $3.60. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53. The stock has a market cap of $2.68 billion, a PE ratio of -3.41 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. Equities research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.